To Get Help Now
Click Here
Today's Date:

Class Action Filed Against Actos Over Bladder Cancer Risk

AddThis Social Bookmark Button

The class action lawsuit was filed in September in the U.S. District Court of the Eastern District of Louisiana on behalf of two Actos users who developed bladder cancer, as well as the spouse of the plaintiffs. The suit was filed against Actos manufacturer Takeda Pharmaceuticals and Eli Lilly, on behalf of the millions who have used the diabetes drug since it hit the market in 1999.

The findings of a 10 year epidemiological study of 193,099 diabetic patients by the manufacturer, which were released this past June, have created enough worry that Actos has already been banned in France and Germany because of its risk. The FDA is now advising doctors to warn patients of the risk when prescribing the medication. Further, the FDA noted in its June 15, 2011 Drug Safety Communication concerning risks of bladder cancer from use of pioglitazone:

“[C]ompared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40% increase in risk.”

“Clearly, the relationship between Actos and bladder cancer has been known, or should have been known, to Defendants,” the lawsuit said. “Despite their knowledge, Defendants refused to inform patients, doctors or the medical community about the risks and put their profits before people.”

The U.S. Judicial Panel on Multidistrict Litigation will decide this year whether or not the 50 lawsuits and one class action against Actos should be centralized for pretrial proceedings. disclaimer: This article: Class Action Filed Against Actos Over Bladder Cancer Risk was posted on Thursday, October 13th, 2011 at 7:45 pm at and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.